A PHARMA services company based in Hartley Wintney has strengthened its team with a raft of senior hires as it continues to grow internationally.
TMC Pharma Services (TMC), which enables Pharma/Biotech companies to develop innovative treatments for rare diseases and oncology, has named Stewart Sharpe as its new chief commercial officer (CCO).
Mr Sharpe joins as CCO from his VP role at Syneous Health, and will oversee the company’s continued UK and international success.
The firm has also brought on board a new head of strategic planning, VP of clinical services, and head of medical services, two of which are entirely new roles.
READ MORE: Inspire Business Awards: Employer of the Year
Rondeep (Ronnie) Bhui has been appointed as head of strategic planning.
Dr Victoria Datsenko is the new VP clinical services, while Dr Marcelo Vaz is the head of medical services.
After securing £18m minority investment from private equity partner LDC last year, TMC has increased its headcount by more than 20 per cent.
Seeking to capitalise on the positive market dynamics, the company has also appointed biotech industry veteran Gordon Cameron as a non-executive director.
With its UK headquarters in Hartley Wintney and subsidiaries in the EU and Japan, TMC works predominantly with clients in North America, EU and Asia.
The company provides comprehensive medicinal product development support, from pre-clinical to post-marketing, for human medicines and devices, including all strategic and hands-on activities.
SEE ALSO: Pitches from Camrose fund won't be exclusively for Basingstoke Town
Chief executive officer Julie Matthews said: “We’re thrilled to be welcoming so many experienced and well-respected healthcare professionals to our team. They each have wide-ranging experience of growing businesses on an international scale and, as we continue to pursue expansion in the USA, Asia and other key global territories, they will be a huge asset in helping us to achieve our goals.
"Our strong growth over the last year, supported by LDC’s experience and network, has meant we’re well positioned to attract exceptional industry talent and I believe we’ve built the perfect platform to accelerate our international growth as a result.”
LDC’s investment director Stefan Gunn said: “The global pharmaceutical market continues to evolve and flourish, which means there’s considerable demand for highly-qualified people who have the right combination of industry experience and commercial insight that can help businesses to achieve their objectives. With this latest series of senior appointments, TMC has secured a number of big-hitters from the industry and their combined experience will bring additional expertise to support TMC’s global customer base as the company continues its growth journey."
Comments: Our rules
We want our comments to be a lively and valuable part of our community - a place where readers can debate and engage with the most important local issues. The ability to comment on our stories is a privilege, not a right, however, and that privilege may be withdrawn if it is abused or misused.
Please report any comments that break our rules.
Read the rules here